Article
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Lancet (London, England) - 7 May 2016
Rosenberg Jonathan E, Hoffman-Censits Jean, Powles Tom, van der Heijden Michiel S, Balar Arjun V, Necchi Andrea, Dawson Nancy, O'Donnell Peter H, Balmanoukian Ani, Loriot Yohann, Srinivas Sandy, Retz Margitta M, Grivas Petros, Joseph Richard W, Galsky Matthew D, Fleming Mark T, Petrylak Daniel P, Perez-Gracia Jose Luis, Burris Howard A, Castellano Daniel, Canil Christina, Bellmunt Joaquim, Bajorin Dean, Nickles Dorothee, Bourgon Richard, Frampton Garrett M, Cui Na, Mariathasan Sanjeev, Abidoye Oyewale, Fine Gregg D, Dreicer Robert
Abstract excerpt
BACKGROUND: Patients with metastatic urothelial carcinoma have few treatment options after failure of platinum-based chemotherapy. In this trial, we assessed treatment with atezolizumab, an engineered humanised immunoglobulin G1 monoclonal antibody that binds selectively to programmed death ligand 1 (PD-L1), in this patient population. METHODS: For this multicentre, single-arm, two-cohort, phase 2 trial, patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.